| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 04/19/2005 | US6881731 Enhancers for microbiological disinfection |
| 04/19/2005 | US6881724 Use of magnesium (Mg2+) for the preparation of a therapeutic composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy |
| 04/19/2005 | US6881575 Using fluorescent activated cell sorting to separate and isolate cells comprising mutations in cell proliferation; anticarcinogenic agents; antiproliferative agents |
| 04/19/2005 | US6881548 Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy |
| 04/19/2005 | US6881409 Compositions and methods for promoting nerve regeneration |
| 04/19/2005 | CA2334155C Cyclic boroproline compounds |
| 04/19/2005 | CA2315189C Integrin receptor antagonists |
| 04/19/2005 | CA2273894C Novel n-benzenesulphonyl-l-proline derivatives, method for preparing and therapeutic use |
| 04/19/2005 | CA2265252C Angiogenic factor and use thereof in treating cardiovascular disease |
| 04/19/2005 | CA2138150C 4-amino-n-(4-methyl-4-piperidinyl)-2-methoxybenzamides |
| 04/19/2005 | CA2059137C Enhancement of musculature in animals |
| 04/16/2005 | CA2480199A1 Fp-ghrelin |
| 04/14/2005 | WO2005033338A1 Method of evaluating risk for viral infection |
| 04/14/2005 | WO2005033109A1 Triazinoindolamine compound |
| 04/14/2005 | WO2005033103A1 Quinoline compounds and their uses |
| 04/14/2005 | WO2005032579A1 Method of regenerating human tissue |
| 04/14/2005 | WO2005032570A1 Dietetic composition |
| 04/14/2005 | WO2005032568A1 Immunopotentiator, antiulcer agent and processed foods comprising fermented soybean product and process for producing fermented soybean product |
| 04/14/2005 | WO2005032552A1 Hypnotic composition |
| 04/14/2005 | WO2005032546A1 Hypnotic composition |
| 04/14/2005 | WO2005032543A1 Hypnotic composition |
| 04/14/2005 | WO2005032537A1 Method for preventing and/or treating neurodegenerative diseases |
| 04/14/2005 | WO2005032535A1 Nerve regeneration promoters |
| 04/14/2005 | WO2005032530A1 Pharmaceutical composition for external application |
| 04/14/2005 | WO2005032517A1 Buccal, polar and non-polar spray containing diazepam |
| 04/14/2005 | WO2003063573A3 Method for treating diseases with omega interferon |
| 04/14/2005 | WO2003051287A3 Topical compositions and methods for treatment of adverse effects of ionizing radiation |
| 04/14/2005 | US20050080257 Benzo'fisoindole derivatives with affinity to the ep4 receptor |
| 04/14/2005 | US20050080141 Amino diols useful in the treatment of alzheimer's disease |
| 04/14/2005 | US20050080128 Indoles as naaladase inhibitors |
| 04/14/2005 | US20050080122 Anti-viral compounds |
| 04/14/2005 | US20050080121 for example, 4S-[(naphthalene-2-carbonyl)-amino]-5-(2-oxo-pyrrolidin-3S-yl)-pent-2-enoic acid ethyl ester; treatment of viral infections caused by human rhinoviruses, human polioviruses, human coxsackieviruses, human echoviruses, among others |
| 04/14/2005 | US20050080113 Medicinal compositions |
| 04/14/2005 | US20050080110 Treating Type 2 diabetes and/or obesity; compounds are indoles substituted at position 3 with a (3-(2-(heterocycle-substituted)phenoxy)-2-hydroxypropylamino)alkyl group |
| 04/14/2005 | US20050080108 such as (S)-1-ethyl-5-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-1H-indole-2-carboxylic acid-[2-[benzyl(methyl)amino]-2-oxo-1-phenylethyl]amide; for treatment of obesity and lipid disorders; diabetes |
| 04/14/2005 | US20050080107 Inhibitor of phosphodiesterase enzyme, 2-(4-(3-cyclopentyloxy-4-difluoromethoxyphenyl)-4-cyanopiperidin-1-yl)acetic acid monohydrate; treating inflammatory diseases, diabetics, allergic diseases, autoimmune diseases, ocular diseases, osteoporosis, Parkinson's disease, dementia; chemical intermediates |
| 04/14/2005 | US20050080106 Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes |
| 04/14/2005 | US20050080099 Methods and kits for treating depression or preventing deterioration of cognitive function |
| 04/14/2005 | US20050080097 5-[1-(hydroxymethyl)propyl]amino-7-benzylamino-3-isopropyl(methyl, ethyl)pyrazolo[4,3-d]pyrimidine for inhibiting cell proliferation, cancer, or psoriasis, rheumatoid arthritis, lupus, diabetes, multiple sclerosis, restenosis, polycystic kidney disease, graft rejection, and neurodegerative diseases |
| 04/14/2005 | US20050080096 Condensed heterocyclic compounds |
| 04/14/2005 | US20050080073 Sulfonylaminocarboxiylic acid N-arylamides as guanylate cyclase activators |
| 04/14/2005 | US20050080071 Treatment methods |
| 04/14/2005 | US20050080067 Omega aminoalkylamides of R-2 aryl propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells |
| 04/14/2005 | US20050080062 preventing or delaying the progression of hormone receptor breast cancer following estrogen antagonist therapy by subsequent therapy with an estrogen depleting agent prior to disease progression |
| 04/14/2005 | US20050080057 reducing weight in mammals; Substituted with a thio, sulfoxy or sulfonyl group eg 5-Chloro-2-methylsulfonylindan-1-ol, 5-Chloro-2-(propane-2-sulfonyl)indan-1-ol, 5-Chloro-2-ethanesulfonylindan-1-ol |
| 04/14/2005 | US20050080050 Lipid analogs for treating viral infections |
| 04/14/2005 | US20050080045 topical administration; prevention of STDs preferably a viral disease other than HIV, e.g. HPV or genital herpes and especially acyclovir resistant genital herpes |
| 04/14/2005 | US20050080030 Amplifying efficiency of transfection, providing aggregation, exposing to vector, monitoring efficiency of transfection |
| 04/14/2005 | US20050080022 substituted benzylphenol derivatives as intermediates for glucopyranosyloxybenzylbenzene derivatives; agents for the prevention or treatment of diabetes, diabetic complications, obesity or the like |
| 04/14/2005 | US20050080018 In particular, use of propionyl-L-carnitine in combination with one or more known useful drugs for preparing medicine for treatment of erectile dysfunction in patients suffering from diabetes mellitus, wherein patients do not respond to treatment with other useful drugs |
| 04/14/2005 | US20050080012 Comprising controlled substance and amino acid or polypeptide covalently bound to controlled substance in manner that renders controlled substance pharmacologically inactive; when delivered by oral route controlled substance is released in time-dependent manner by acid hydrolysis and/or enzyme cleavage |
| 04/14/2005 | US20050080010 Suppression of immune response via inhibition of cathepsin S |
| 04/14/2005 | US20050080006 Apo2L/TRAIL formulations including lyophilized and crystal compositions; may be used in inducing apoptosis in mammalian cells including cancer cells by exposing mammalian cells to an effective amount of an Apo-2 ligand formulation described herein |
| 04/14/2005 | US20050079575 Human receptor molecules |
| 04/14/2005 | US20050079502 Transplant rejection suppressor |
| 04/14/2005 | US20050079495 Modified membrane protein comprising proteolytic and is absent for g-protein coupling for use as tool in diagnosis, prevention and treatment of pain, arthritis, asthma, psychological and gastrointestinal disorders |
| 04/14/2005 | US20050079217 Tablet with protective coatings; Parkinson's disease; sexual disorders |
| 04/14/2005 | US20050079176 Treating stress response with chemokine receptor ccr5 modulators |
| 04/14/2005 | US20050079159 Autologous tissue for connecting structures; regeneration of tissue; cell differentiation of pluripotent cells |
| 04/14/2005 | US20050079156 Method of treating endometreosis |
| 04/14/2005 | US20050079148 Biocompatible polymer designed to release nitric oxide; extensively cross-linked polyamine-derivatized divinylbenzene; sustained release, potentiation |
| 04/14/2005 | DE202005000948U1 Zusammensetzung zur Behandlung der Apnoe, des Schnarchens und von Schlafstörungen Composition for the treatment of apnea, snoring and sleep disorders |
| 04/14/2005 | DE10345065A1 Aerosolformulierung für die Inhalation enthaltend ein Anticholinergikum Aerosol formulation for inhalation containing an anticholinergic |
| 04/14/2005 | CA2582007A1 Buccal, polar and non-polar spray containing diazepam |
| 04/13/2005 | EP1522584A2 Phosphatidylinositol 3-kinase p110 delta catalytic subunit |
| 04/13/2005 | EP1522579A2 Hyaluronan synthase gene and uses thereof |
| 04/13/2005 | EP1522543A1 Use Steroid sulphatase inhibitors for the manufacture of a medicament for the treatment of an oestrogen dependent tumour |
| 04/13/2005 | EP1522540A1 Azaarene derivatives |
| 04/13/2005 | EP1522539A1 Crystalline composition containing escitalopram |
| 04/13/2005 | EP1522314A1 Remedies for diseases caused by vascular contraction or dilation |
| 04/13/2005 | EP1522313A1 Combination therapy of radiation and valdecoxib for the treatment of neoplasia |
| 04/13/2005 | EP1522310A1 Therapeutic uses of dunaliella powder |
| 04/13/2005 | EP1521963A2 Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby |
| 04/13/2005 | EP1521839A1 Methods of making viral particles having a modified cell binding activity and uses thereof |
| 04/13/2005 | EP1521832A2 Genes |
| 04/13/2005 | EP1521824A2 Nucleic acid-associated proteins |
| 04/13/2005 | EP1521757A1 Novel tricyclic spiropiperidines or spiropyrrolidines |
| 04/13/2005 | EP1521754A2 Viral inhibitors |
| 04/13/2005 | EP1521735A2 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals |
| 04/13/2005 | EP1521733A1 Modulators of the glucocorticoid receptor |
| 04/13/2005 | EP1521597A1 LIQUID FORMULATIONS WITH HIGH CONCENTRATION OF HUMAN GROWTH HORMONE (hgh) COMPRISING 1,2-PROLPYLENE GLYCOL |
| 04/13/2005 | EP1521596A1 Liquid formulations with a high concentration of human growth hormone (hgh) comprising glycine |
| 04/13/2005 | EP1521595A1 Novel drug compositions based on novel anticholinergics and inhibitors of egfr-kinase |
| 04/13/2005 | EP1521588A2 Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors |
| 04/13/2005 | EP1521584A1 Purine derivatives as liver x receptor agonists |
| 04/13/2005 | EP1521583A1 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2h-pyrrolo (2,1-b)-quinazolinone derivatives |
| 04/13/2005 | EP1521580A1 Novel pharmaceutical compositions comprising novel anticholinergic agents and nk1-receptor antagonists |
| 04/13/2005 | EP1480736A4 Microcapsules having high carotenoid content |
| 04/13/2005 | EP1366050B1 Condensed pyrazindione derivatives as pde inhibitors |
| 04/13/2005 | EP1303296B1 Composition containing an iron complexing protein and a precursor of nitrogen monoxide metabolism and/or a chemical donor of nitrogen monoxide and uses thereof |
| 04/13/2005 | EP1289955B1 Piperidines for use as orexin receptor antagonists |
| 04/13/2005 | EP1268498B1 Cardioprotective phosphonates |
| 04/13/2005 | EP1212052B1 Therapeutic uses of polymers and oligomers comprising gamma-hydroxybutyrate |
| 04/13/2005 | EP1196136B1 Compositions comprising organosiloxane resins for delivering oral care substances |
| 04/13/2005 | EP1183353B1 Modified chimeric polypeptides with improved pharmacokinetic properties |
| 04/13/2005 | EP1115409A4 Composition for extending post meal satiety |
| 04/13/2005 | EP1090105B1 Non-embryonic ependymal neural stem cells and method for their isolation |
| 04/13/2005 | EP1073640B1 Naphthalene derivatives, their production and use |
| 04/13/2005 | EP1073453B1 Use of angiotensin analogs for the manufacture of a medicament for increasing white blood cell survival and mobilizing haematopoietic progenitor cells following chemotherapy |
| 04/13/2005 | EP0975349B1 Serine proteinase inhibitory activity by hydrophobic tetracycline |